bpc-157 origin gastric derived Stable Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System BPC-157 Peptide: Benefits for Healing,

Journal of Analytical Oncology, 3 (2), 79-87

Their rapid absorption ensures effective results, making them an excellent option for individuals seeking a natural boost in energy and metabolism

Mez J, Daneshyar DH, Kiernan PT, Abdolmohammadi B, Alarez VE, et al

Diagen is the company that currently owns the BPC-157 US patent (the European patent is expired), which was filed in 2012, approved in 2017 with an expected expiration of 2033

With these results in hand we became convinced that a clinically useful small molecule analog could be designed that possessed the important characteristics of metabolic stability, extended half-live, BBB penetrability and the capability to enhance cognitive functioning